Research programme: RGD-targeted MMAE-albumin conjugates - Seattle Genetics

Drug Profile

Research programme: RGD-targeted MMAE-albumin conjugates - Seattle Genetics

Alternative Names: RGD-MMAE-HSA; RGDPEG-MMAE-HSA

Latest Information Update: 07 Dec 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Seattle Genetics
  • Class
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 07 Dec 2005 Preclinical trials in Cancer in Netherlands (IV)
  • 07 Dec 2005 Data presented at the 17th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2005) have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top